Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cancer Proteomics

Ruedi Aebersold's Biography



Ruedi Aebersold, Professor, Institute for Systems Biology

Prof. Ruedi Aebersold is one of the pioneers in the field of proteomics. He is known for developing a series of methods that have found wide application in analytical protein chemistry and proteomics like a new class of reagents termed Isotope Coded Affinity Tag (ICAT) reagents used in quantitative mass spectrometry. Prof. Dr. Aebersold and his team of researchers use the protein profiles determined by this method to differentiate cells in different states, such as noncancerous versus cancerous cells, and to systematically study how cells respond to external stimuli. These "snapshot" profiles indicate which cells contain abnormal levels of certain proteins. This is expected to lead to new diagnostic markers for disease and to a more complete understanding of the biochemical processes that control and constitute cell physiology.
Prof. Aebersold serves on the Scientific Advisory Committees of numerous academic and private sector research organizations and is a member of several editorial boards in the fields of protein science, genomics, and proteomics.
Prof. Aebersold is a native of Switzerland and obtained his Ph.D. in Cellular Biology at the Biocenter of the University of Basel in 1983. Since that time, he is a faculty member of the Universities of Washington and British Columbia, until 2000, when he co-founded the Institute for Systems Biology in Seattle. In 2004, he accepted a position as full professor at the Institute of Biotechnology at the Swiss Federal Institute of Technology (ETH) in Zurich, where in January 2005, his research group became the first integral part of the newly founded Institute of Molecular Systems Biology.

Ruedi Aebersold Image

Mass Spectrometric Strategies for Protein Biomarker Discovery and Validation

Tuesday, 16 October 2012 at 14:45

Add to Calendar ▼2012-10-16 14:45:002012-10-16 15:45:00Europe/LondonMass Spectrometric Strategies for Protein Biomarker Discovery and Validation SELECTBIOenquiries@selectbiosciences.com

In this presentation we will discuss this novel biomarker strategy, its present status and expected directions.  A case study on PTEN dependent prostate cancer will illustrate the concept.


Add to Calendar ▼2012-10-16 00:00:002012-10-17 00:00:00Europe/LondonCancer ProteomicsSELECTBIOenquiries@selectbiosciences.com